ConductScience.org, home

Comparison · NCT00179777-6cda80a4

Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: Number of Participants With Type 1 Diabetes Mellitus

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: Number of Participants With Type 1 Diabetes Mellitus. Trial comparisons, record NCT00179777-6cda80a4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00179777-6cda80a4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.07610.06170.0934wilson
Risk in group 20.08420.06910.102wilson
Risk difference, group 1 minus group 2-0.00811-0.03120.0149newcombe hybrid score
Risk ratio, group 1 over group 20.9040.6791.2log
Odds ratio, group 1 over group 20.8960.6561.22log
Number needed to treat, for one fewer participant with the outcome on Nonhydrolysed Infant Formula than on Hydrolysed Infant Formula123from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Nonhydrolysed Infant FormulaNumber of participants diagnosed with type 1 diabetes821,078OG000
Group 2Hydrolysed Infant FormulaNumber of participants diagnosed with type 1 diabetes911,081OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Type 1 Diabetes Mellitus
Description
Number of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study.
Time frame
12 and 18 months and annually from 2 years up to 14 years
Population
Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes

Source ClinicalTrials.gov

Trial

Title
TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk
NCT number
NCT00179777
Phases
NA
Conditions
Diabetes Mellitus, Type 1
Interventions
Hydrolysed infant formula, Nonhydrolysed infant formula
Lead sponsor
University of Helsinki
Results first posted
2021-07-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00179777-6cda80a4